Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP) distribution and sales agreement in Israel with TrueMed Ltd. According to Race, TrueMed is a pharmaceutical distributor with...
Race appoints BioSynergy to pursue Bisantrene licensing
Race appoints BioSynergy to pursue Bisantrene licensing
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy Partners LLC (BioSynergy) to pursue licensing and other deals for Bisantrene (the ‘Agreement’). BioSynergy is a transaction consulting business owned...
Race appoints US consultant to drive partnering, investment, clinical funding
Race appoints US consultant to drive partnering, investment, clinical funding
Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to assist Race with partnering and funding opportunities in the US, with a focus on Houston, Texas. Mr Lee...
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood Acute Myeloid Leukaemia (AML)....
Long-term survival case report of patients treated with Bisantrene Combination Therapy
Long-term survival case report of patients treated with Bisantrene Combination Therapy
The poster below details the long-term survival case report of two paediatric relapsed or refractory Acute Myeloid Leukemia patients treated with Bisantrene Combination Therapy....
Bisantrene granted unlicensed medicine approval in UK
Bisantrene granted unlicensed medicine approval in UK
Race Oncology is pleased to announce that approval has been received from the Medicines and Healthcare products Regulatory Agency (MHRA) for importation and distribution of Bisantrene as an unlicensed medicine in the UK. The...
French doctors hail Race’s Bisantrene in new case report
French doctors hail Race’s Bisantrene in new case report
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene to treat childhood relapsed/refractory AML (Acute Myeloid Leukaemia). The report will be published at a forthcoming oncology conference in...
Race appoints former Sanofi executive to the Board
Race appoints former Sanofi executive to the Board
Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and Schering-Plough in the...
Viralytics sale signals positive outlook for Race
Viralytics sale signals positive outlook for Race
In a major development for the Australian biotech sector, ASX-listed oncology drug developer, Viralytics, has been sold to US-based big pharma, Merck, for US$502 million. As a former Director of Viralytics from 2008 –...
Second Bisantrene Patent allowed in US
Second Bisantrene Patent allowed in US
Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled, “Compositions to Improve the Therapeutic...
